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Elotuzumab, lenalidomide, and dexamethasone as
salvage therapy for patients with multiple myeloma:
Italian, multicenter, retrospective clinical experience
with 300 cases outside of controlled clinical trials
Recently, monoclonal antibodies (mAb) directed to
antigens expressed by plasma cells demonstrated major
clinical activity in multiple myeloma (MM), thus gaining
a relevant role in the treatment of MM patients.1 Two
mAb targeting signaling lymphocytic activation, mole-
cule F7 (SLAMF7/CS1) and CD38, have been increasingly
included in relapse/refractory (RR) MM (RRMM) thera-
peutic regimens.2 Among them, elotuzumab (Elo), targets
the glycoprotein receptor SLAMF7 causing, on the one
side, activation of natural killer cells, and on the other,
myeloma cell death through antibody-dependent cellular
cytotoxicity (ADCC).3,4 Surprisingly, Elo failed to demon-
strate significant anti-tumor activity as single-agent,5 ulti-
mately refining its anti-myeloma action in combination
with immunomodulatory drugs (IMiD) such as lenalido-
mide (R). A randomized phase III clinical trial comparing
the clinical benefits of R plus dexamethasone (Rd) versus
Rd plus Elo (EloRd) resulted in a longer progression-free
survival (PFS) in patients allocated to the experimental
arm.6Moreover, extended assessments at 3-year,7 4-year,8
and 5-year9 follow-ups showed a significantly higher
overall response rate (ORR) for EloRd as compared to the
Rd regimen. Accordingly, the addition of Elo to Rd signif-
icantly reduced the risk of death by 27%.8
Here we report data of an Italian 'real-life' experience
on EloRd as therapy for RRMM patients treated outside
of controlled clinical trials, after receiving marketing
approval in Italy in April 2017.
Overall, 300 RRMM patients treated with EloRd
according to the marketing approved schedule between
April 2017 and April 2019 at 40 Italian centers entered
this study (Online Supplementary Methods). Baseline char-
acteristics are shown in Table 1. Approximately one quar-
ter of patients (24.3%) had resistance to their most recent
line of therapy, symptomatic relapse was observed in 171
patients (57%), and a biochemical relapse in 56 (18.7%).
Over one-third (38.3%) received autologous stem cell
transplant (ASCT), while 26% of patients had received
prior lenalidomide treatment. Fluorescence 
in situ hybridization (FISH) data were available in only 64
patients; ten patients showed high-risk abnormalities.
Thirty patients with mild renal impairment received R at
the starting dose of 10 mg, while 24 with severe renal
impairment received the starting dose of 15 mg every
other day; 123 elderly patients (>75 years) received a
weekly dose of 20 mg.
At the time of last database update, the median num-
ber of courses administered was 12 (range, 1-43). A total
of 188 (62.7%) patients stopped EloRd treatment at the
time of the cut-off date (median follow-up: 19 months
[range 1–36 months]) mainly owing to disease progres-
sion (151 cases), 13 patients for toxicity (9 infections, 2
lenalidomide-related severe skin rash, one dexametha-
sone-related psychosis, and one lenalidomide-related
hepatotoxicity), 22 patients due to therapy-unrelated
deaths, while two patients underwent ASCT. Infusion
reactions occurred in 19 patients (6.3%, all grade 1-2) and
were promptly resolved in all patients (no discontinua-
tion reported). Major adverse events (AE) are shown in
Table 2 and included grade 3/4 neutropenia (19%), ane-
mia (15.7%), lymphocytopenia (12.7%), and thrombocy-
topenia (10%) while infection rates and pneumonia were
approximately 34% and 16%, respectively. Notably,
there was no significant difference in incidence of AE
between younger (≤75 years) and elderly patients (data
not shown).
Age is an important factor in the treatment decision-
making process for MM patients because of its associa-
tion with frailty, increased comorbidities, poor tolerabili-
ty, and higher risk of complications.10 In our series,
approximately 41% of patients were aged ≥75 years, and
Table 1. Main characteristics of patients at baseline.
                                                                             N. of patients (%)
Age, (years)                                                                                       
<75                                                                                           177 (59)
≥75                                                                                           123 (41)
Sex
Male                                                                                       157 (52.3)
Female                                                                                   143 (47.7)
Paraproteins (isotype)
Immunoglobulin G                                                              188 (62.7)
Immunoglobulin A                                                               55 (18.2)
Immunoglobulin D                                                                 2 (0.7)
Light chain only                                                                    53 (17.7)
Non-secretory                                                                        2 (0.7)
Creatinine clearance (mL/min)
≥60                                                                                         214 (71.3)
<60                                                                                          86 (28.7)
Stage ISS, (n=238)
I                                                                                                91 (38.3)
II                                                                                               95 (39.9)
III                                                                                             52 (21.8)
Number of previous lines of therapy
1                                                                                                186 (62)
2                                                                                               70 (23.3)
3                                                                                                20 (6.7)
34                                                                                                  24(8)
Previous ASCT
No                                                                                           185 (61.7)
Yes                                                                                          115 (38.3)
Previous therapies
Bortezomib                                                                            282 (94)
Lenalidomide                                                                         78 (26)
Cytogenetic profile 
Standard risk                                                                         49 (16.3)
High risk*                                                                               10 (3.3)
Not evaluated                                                                       241 (80.4)
Disease status 
Biochemical relapse                                                           56 (18.7)
Symptomatic relapse                                                           171 (57)
Refractory to last treatment                                             73 (24.3)
Time from diagnosis to EloRd treatment (years)
≥3.5                                                                                        154 (51.3)
<3.5                                                                                       146 (48.7)
N: number; ISS: International Staging System; ASCT: autologous stem cell transplant;
EloRd: lenalidomide plus dexamethasone (Rd) plus elotuzumab. *Patients harbor-
ing a t(4;14), t(14;16), or del(17p) were classified as having high-risk disease and
all other cases as being at standard risk.
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of these about 29% presented with renal impairment. In
addition, the Eloquent-2 phase III trial6 and subsequent
updates7-9 have suggested that this triplet drug regimen is
safe. Although these results should be treated with some
caution given the retrospective nature of the present
study and the different clinical features of patients includ-
ed in the two series (i.e., the median number of previous
lines of therapies, 2 in the Eloquent-2 trial and one in our
retrospective series), our real-world cohort documented
similar AE profiles, except lymphopenia incidence, possi-
bly due to the above mentioned median number of pre-
vious lines of therapies and the reduced dexamethasone
dose for patients >75 years. Of note, no significant differ-
ences in terms of incidence of AE were documented
between younger (<75 years) and elderly patients. Thus,
the choice of adding elotuzumab to Rd seems to have
been rewarded by the clinical benefit observed in our
'real-world' cohort, and as previously described, in the
Eloquent-2 phase III trial6-9 across key subgroups includ-
ing elderly patients, as well as in individuals with a
reduced renal function, thus offering a paradigm for case
selection.11
The ORR was 77%, with 23 complete remissions (CR)
(7.6%) and 88 very good partial remissions (VGPR)
(29.3%). The median time to first response was 1.7
months, while the median time to best response was 3.5
Figure 1. Progression-free survival (PFS) of the retrospective cohort of relapse/refractory (RR) multiple myeloma patients treated with lenalidomide plus dex-
amethasone (Rd) plus elotuzumab (EloRd). Kaplan-Meier curve of PFS of the entire cohort (A). Forest plot of Cox univariate analysis for PFS according to clinical
laboratory variables (B). b2M: beta-2-microglobulin; ASCT: autologous stem cell transplant; CrCl: creatinine clearance; CRAB: hypercalcemia, renal failure, ane-
mia, and bone disease; N: number.
A
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months (Online Supplementary Figure S1) with approxi-
mately 73% and 91% of patients reaching the best
response at 6 and 12 months, respectively. The ORR of
our 'real-world' cohort was comparable with that of the
Eloquent-2 trial (77% vs. 79%),6with a similar number of
patients reaching good quality responses. Moreover, the
median time to achieve the best response was 3.5
months as compared to 2.8 months according to the
Eloquent-2 independent review and 3.8 months based on
the investigators’ assessment.6
Among the variables analyzed, a significantly worse
treatment response was observed among patients previ-
ously exposed to lenalidomide and those with refractory
disease status at EloRd start (Online Supplementary Table
S1). However, the association between response and dis-
ease status at EloRd was no longer significant after
Bonferroni correction. Nevertheless, in the light of the
etiological nature of our study, multivariate ordinal
regression analysis was still performed, showing prior
lenalidomide exposure as the unique variable adversely
and independently associated with the best response
(odds ratio: 2.04, 95%CI: 1.2-3.3; P=0.005). Thus, prior
lenalidomide exposure should be considered to be an
additional concern when choosing EloRd treatment.
During the follow-up period, 173 patients out of 300
experienced disease progression or died; 94 patients died.
Median PFS was 17.6 months (95%CI: 14.1-21.0), and
the 1-year PFS was 59.1% (Figure 1A), both results were
very similar to the 19.4 months and 68% determined in
the Eloquent-2 trial.6 Univariate Cox analyses showed
that refractory disease status at EloRd initiation
(HR:1.572, 95%CI: 1.054-2.345; P=0.027), a shorter time
(i.e., <3.5 years) from diagnosis to EloRd start (HR:1.505,
95%CI: 1.036-2.187; P=0.032), more than two previous
lines of therapy (HR:1.777, 95%CI: 1.227-2.572;
P=0.002), and serum albumin level below 35 g/L
(HR:1.849, 95%CI: 1.241-2.757; P=0.003) were associat-
ed with a significantly higher risk to progress or of death
(Figure 1B). Notably, in the multivariate Cox model, albu-
min <35 g/L (HR:1.721, 95%CI: 1.147-2.581; P=0.009),
time from diagnosis to EloRd start <3.5 years (HR:1.811,
95%CI: 1.179-2.781; P=0.007), and >2 lines of previous
therapy (HR:2.116, 95%CI: 1.39-3.22; P<0.0001) main-
tained an independent prognostic impact on PFS. 
This multivariate model confirmed the Eloquent-2 trial
results,6 demonstrating that those cases with a short dis-
ease history could be more prone to progress. Notably, a
precocious EloRd treatment in MM patients with asymp-
tomatic biochemical relapse failed to improve PFS in our
series, strengthening the concept that only patients with
recurrence of the most typical clinical manifestations of
MM (hypercalcemia, renal failure, anemia, and bone dis-
ease; CRAB) should start treatment. 
Moreover, ten cases with high-risk cytogenetic abnor-
malities showed a significantly shorter PFS than 54 cases
with standard risk (Online Supplementary Figure S2).
Nevertheless, the low number of evaluated cases (19.6%)
does not allow any conclusions to be drawn regarding
efficacy of EloRd in high-risk patients.
Another objective of this analysis was to determine the
relationship between the quality of response and PFS.
EloRd-treated patients who achieved ≥VGPR were asso-
ciated with higher PFS rates compared with EloRd-treat-
ed patients who achieved a partial response (PR) or less
(Online Supplementary Figure S3). The results of Cox
regression are detailed in the inbox in Online
Supplementary Figure S3.  Specifically, PFS rates at one
year were approximately 80.1% (HR:1, reference group),
59% (HR: 2.15, 95%CI: 1.46-3.16; P<0.0001), and 23.8%
(HR: 6.74, 95%CI: 4.47-10.15; P<0.0001) for cases
achieving ≥VGPR, partial response (PR), and <PR, respec-
tively (Online Supplementary Figure S3). Interestingly, no
difference was demonstrated between complete remis-
sion (CR)/near CR (nCR) cases as compared with those
achieving VGPR.
The median time-to-next-treatment (TTNT) (25.3
months ([95%CI: 22.1-28.3]) (Online Supplementary Figure
S4) of our 'real-world' cohort was comparable to that of
the Eloquent-2 trial (25.3 vs. 33.4 months).7
Finally, median overall survival (OS) was not reached
and 1-year OS was 65.5% (Online Supplementary Figure S5).
To our knowledge, our survey is one of the largest
EloRd series in terms of number of patients evaluated.
This regimen represents one example of five triple sched-
ules that have received high-level evidence and uniform
consensus as a preferred treatment regimen for patients
with RRMM.12,13
In conclusion, our 'real-world' cohort clearly showed
that EloRd was a safe and effective regimen for RRMM
patients, confirming the results obtained in the 
Eloquent-2 controlled clinical trial.6-9 Based on both stud-
ies, we suggest incorporating EloRd as a first salvage reg-
imen in lenalidomide naïve patients and in patients with
relatively longer disease duration. New ongoing trials
will assess the efficacy of elotuzumab either in combina-
tion or with other IMiD14 in the context of an intensified
treatment algorithm.15
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Table 2. Incidence of serious adverse events. 
                                                                        EloRd (n=300)
Grade 3/4 adverse events                                        N. of cases (%)
Hematologic toxicities
Lymphocytopenia                                                        38 (12.7)
Anemia                                                                           47 (15.7)
Thrombocytopenia                                                       30 (10)
Neutropenia                                                                   57 (19)
Non-hematologic toxicities
Infections                                                                     103 (34.3)
Pneumonia                                                                    50 (16.7)
Fatigue                                                                           62 (20.7)
Diarrhea                                                                         22 (7.3)
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